谢娜，副研究员，主要从事病毒诱导肿瘤发生发展过程中的相互作用网络、氧化应激、代谢调控和细胞自噬等机理及干预策略研究，以第一作者或通讯作者（含共同）在
Signal Transduct Target Ther、Autophagy、Small、J Hematol Oncol、J Adv Res、Theranostics、Cancer Lett
等国际学术期刊发表20余篇学术论文，其中4篇入选ESI高被引论文。
代表性论文
1.
Xie N
*, Shen G*, Gao W, Huang Z, Huang C#, Fu L#. Neoantigens: promising targets for cancer therapy.
Signal Transduct Target Ther
. 2023;8(1):9.
2. Li L, Tian H, Zhang Z, Ding N, He K, Lu S, Liu R, Wu P, Wang Y, He B, Luo M, Peng P, Yang M, Nice EC, Huang C,
Xie N
#, Wang D#, Gao W#. Carrier-Free Nanoplatform via Evoking Pyroptosis and Immune Response against Breast Cancer.
ACS Appl Mater Interfaces
. 2023;15(1):452-68.
3. Chen X, Feng L, Huang Y, Wu Y,
Xie N
#. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.
Cancers
. 2023; 15(1):104.
4. Lu S, Tian H, Li L, Li B, Yang M, Zhou L, Jiang H, Li Q, Wang W, Nice EC,
Xie N
#, Huang C#, Liu L#. Nanoengineering a Zeolitic Imidazolate Framework-8 Capable of Manipulating Energy Metabolism against Cancer Chemo-Phototherapy Resistance.
Small
. 2022: e2204926.
5. Duan J, Huang Z, Nice EC,
Xie N
#, Chen M#, Huang C#. Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling.
J Adv Res
. 2022:S2090-1232(22) 00188-6.
6. Tian H, Zhang T, Qin S, Huang Z, Zhou L, Shi J, Nice EC,
Xie N
#, Huang C#, Shen Z#. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.
J Hematol Oncol
. 2022;15(1):132.
7. Zhang Y, Li J, Gao W#,
Xie N
#. Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges.
Front. Biosci. (Landmark Ed)
. 2022;27(10):293.
8. Wu P, Han J, Gong Y, Liu C, Yu H#,
Xie N
#. Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications.
Pharmaceutics
. 2022;14(10):1990.
9. An Y, Jiang J, Zhou L, Shi J, Jin P, Li L, Peng L, He S, Zhang W, Huang C, Zou B#,
Xie N
#. Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma.
Cancer Lett
. 2021; 521:210-23.
10. Huang Z*,
Xie N
*, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu SG, Huang C, Tang Y. From purines to purinergic signalling: molecular functions and human diseases.
Signal Transduct Target Ther
. 2021; 6(1): 162. (
ESI高被引论文
)
11. Wu P*, Gao W*, Su M, Nice EC, Zhang W, Lin J#,
Xie N
#. Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment.
Front Cell Dev Biol
. 2021; 9: 357. (
ESI高被引论文
)
12.
Xie N
*, Zhang L*, Gao W*, Huang C, Huber PE, Zhou X, Li C#, Shen G#, Zou B#. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.
Signal Transduct Target Ther
. 2020;5(1):227. (
ESI高被引论文
)
13. Peng L, Jiang J, Tang B, Nice EC, Zhang YY#,
Xie N
#. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.
Theranostics
. 2020; 10(23):10360-77.
14. Zhang Z*, Zhou L*,
Xie N
*, Nice EC, Zhang T, Cui Y, Huang C. Overcoming cancer therapeutic bottleneck by drug repurposing.
Signal Transduct Target Ther
. 2020;5(1):113. (
ESI高被引论文
)
15.
Xie N
*, Yuan K*, Zhou L, Wang K, Chen HN, Lei Y, Lan J, Pu Q, Gao W, Zhang L, Shen G, Li Q, Xiao H, Tang H, Xiang R, He M, Feng P, Nice EC, Wei Y, Zhang H, Yang J, Huang C. PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation.
Autophagy
. 2016; 12(9): 1507-20.
